Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Drug delivery options for the treatment of ocular inflammation.

Lobo AM, Sobrin L, Papaliodis GN.

Semin Ophthalmol. 2010 Sep-Nov;25(5-6):283-8. doi: 10.3109/08820538.2010.518522. Review.

PMID:
21091013
2.

[Intravitreal triamcinolone acetonide for the treatment of intraocular edematous and neovascular diseases].

Jonas JB, Kreissig I, Kamppeter B, Degenring RF.

Ophthalmologe. 2004 Feb;101(2):113-20. Review. German.

PMID:
14991306
3.

[Intravitreal implants: drug carriers and carriers of hope?].

Winterhalter S, Ruokonen P, van der Velden KH, Pleyer U, Joussen AM.

Ophthalmologe. 2011 Mar;108(3):222-9. doi: 10.1007/s00347-010-2264-y. Review. German.

PMID:
21424918
4.

Drug delivery methods for posterior segment disease.

Hsu J.

Curr Opin Ophthalmol. 2007 May;18(3):235-9. Review.

PMID:
17435432
5.

The pros and cons of intravitreal triamcinolone injections for uveitis and inflammatory cystoid macular edema.

van Kooij B, Rothova A, de Vries P.

Ocul Immunol Inflamm. 2006 Apr;14(2):73-85. Review.

PMID:
16597536
6.
7.

Intravitreal steroids for macular edema: the past, the present, and the future.

Cunningham MA, Edelman JL, Kaushal S.

Surv Ophthalmol. 2008 Mar-Apr;53(2):139-49. doi: 10.1016/j.survophthal.2007.12.005. Review.

PMID:
18348879
8.

The use of intraocular corticosteroids.

Kiernan DF, Mieler WF.

Expert Opin Pharmacother. 2009 Oct;10(15):2511-25. doi: 10.1517/14656560903160671. Review.

PMID:
19761356
9.

[Treatment of oedematous, proliferative and neovascular diseases by intravitreal triamcinolone acetonide].

Jonas JB, Kreissig I, Degenring RF.

Klin Monbl Augenheilkd. 2003 Jun;220(6):384-90. Review. German.

PMID:
12830391
10.

Think global--act local: intravitreal drug delivery systems in chronic noninfectious uveitis.

Hazirolan D, Pleyer U.

Ophthalmic Res. 2013;49(2):59-65. doi: 10.1159/000345477. Review.

11.

New developments in corticosteroid therapy for uveitis.

Taylor SR, Isa H, Joshi L, Lightman S.

Ophthalmologica. 2010;224 Suppl 1:46-53. doi: 10.1159/000318021. Review.

PMID:
20714181
12.

Intravitreal steroids in the management of macular oedema.

Sivaprasad S, McCluskey P, Lightman S.

Acta Ophthalmol Scand. 2006 Dec;84(6):722-33. Review.

13.

Review and update of intraocular therapy in noninfectious uveitis.

Sallam A, Taylor SR, Lightman S.

Curr Opin Ophthalmol. 2011 Nov;22(6):517-22. doi: 10.1097/ICU.0b013e32834bbd68. Review.

PMID:
21897242
14.

The therapeutic potential of intraocular depot steroid systems: developments aimed at prolonging duration of efficacy.

Nentwich MM, Ulbig MW.

Dtsch Arztebl Int. 2012 Sep;109(37):584-90. doi: 10.3238/arztebl.2012.0584. Review.

15.
16.
17.

Intravitreal inserts of steroids to treat diabetic macular edema.

Montero JA, Ruiz-Moreno JM.

Curr Diabetes Rev. 2009 Feb;5(1):26-32. Review.

PMID:
19199895
18.

Update on treatments for diabetic macular edema.

Fraser-Bell S, Kaines A, Hykin PG.

Curr Opin Ophthalmol. 2008 May;19(3):185-9. doi: 10.1097/ICU.0b013e3282fb7c45. Review.

PMID:
18408491
19.

Sustained-release fluocinolone acetonide intravitreal insert for macular edema: clinical pharmacology and safety evaluation.

Sadiq MA, Agarwal A, Soliman MK, Hanout M, Sarwar S, Do DV, Nguyen QD.

Expert Opin Drug Saf. 2015 Jul;14(7):1147-56. doi: 10.1517/14740338.2015.1041916. Review.

PMID:
25994877
20.

Biodegradable intraocular therapies for retinal disorders: progress to date.

Kuno N, Fujii S.

Drugs Aging. 2010 Feb 1;27(2):117-34. doi: 10.2165/11530970-000000000-00000. Review.

PMID:
20104938
Items per page

Supplemental Content

Support Center